News Briefing channel feed

Mer­ck KGaA sells off its biosim­i­lars port­fo­lio in €670M deal; uniQure boost­ed by PRIME; Strug­gling Oph­thotech gets new CEO

9 years ago

Ar­genx files for a $75M IPO; PDU­FA date loom­ing, Bio­Marin wins CHMP nod for Brineu­ra

9 years ago

Cel­gene grabs more space in Cam­bridge; Karolin­s­ka Dev gets new CEO

9 years ago

David Meek­er adds an­oth­er biotech board spot to the post-Gen­zyme re­sume; J&J’s DePuy ac­quires 3D print­ing tech for bone heal­ing

9 years ago

Ther­a­peu­tic­sMD flags “de­fi­cien­cies” in NDA; CRUK, NCI col­lab­o­rate on RAS in­hibitor re­search

9 years ago

Cel­gene, Io­n­is ink Chi­na drug de­vel­op­ment pacts; Mo­tif touts pos­i­tive PhI­II an­tibi­ot­ic da­ta

9 years ago

CRISPR Ther­a­peu­tics, Case­bia ink AAV deal with Stride­Bio; Puma gets an Ad­Comm date; Mer­ri­mack names new R&D chief

9 years ago

Ap­ple’s ‘su­per se­cret’ plan to rev­o­lu­tion­ize di­a­betes care; Thiel’s Break­out Labs takes on 4 more star­tups

9 years ago

No­van shares shoot up on pos­i­tive PhII an­ti-fun­gal gel boast; Apex­i­gen strikes a check­point com­bo agree­ment with Bris­tol-My­ers

9 years ago

PureTech launch­es an I/O start­up in­spired by NYU’s George Miller; SV adopts a new name

9 years ago

Pri­vate eq­ui­ty groups bag Sta­da in $5.6B buy­out; Jef­feries sees de­te­ri­o­rat­ing prospects for As­traZeneca

9 years ago

J&J inks a $1.15B dis­cov­ery deal with Pep­tiDream; Medi­vir plots PhI­II HDAC pro­gram

9 years ago

Adap­ti­m­mune rais­es $106M for pipeline work; Kalo­Bios chief says biotech is on track for Cha­gas drug fil­ing

9 years ago

Thiel-backed Az­i­tra rais­es $3M for skin mi­cro­bio­me R&D; Crushed by clin­i­cal fail­ure, Avi­ra­gen launch­es strate­gic re­view

9 years ago

Al­ler­gan vet takes the CEO’s job at Third Rock’s Re­lay; Verona Phar­ma files $86M IPO

9 years ago

Roche scores a suc­cess for Ale­cen­sa PhI­II; FDA sched­ules Ad­Comm for Hep­lisav-B; New CMO at Sarep­ta

9 years ago

Pro­men­tis rais­es $26M for glu­ta­mater­gic drug R&D; CARB-X of­fers up to $48M for fight­ing drug-re­sis­tant bac­te­ria

9 years ago

LAM rais­es $58M for can­cer, rare dis­ease pipeline; What do you pray for?

9 years ago

Blue­print maps plans for $150M raise; Glax­o­SmithK­line cre­ates dis­cov­ery pact with Warp Dri­ve

9 years ago

Pa­piernik named chair­man at Sofinno­va Part­ners; Cara shares surge on pos­i­tive da­ta for ure­mic pru­ri­tus

9 years ago

Ery­tech shares soar on pos­i­tive re­sults for PhI­Ib pan­cre­at­ic can­cer tri­al; Ar­Qule’s tivan­ti­nib fails yet again in PhI­II can­cer study

9 years ago

FDA starts the pri­or­i­ty re­view clock for Sym­bio­mix; Cor­ner­stone gets a green light on piv­otal stud­ies

9 years ago

Califf cau­tions against low­er­ing FDA stan­dards; Ed­i­tas out­lines $1B mile­stone pack­age

9 years ago

Neu­ro­crine flesh­es out its PhI­II case for val­be­nazine; Avro­bio adds to gene ther­a­py pipeline

9 years ago
First page Previous page 70717273747576 Next page Last page
A service from the Financial Times